PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

未开盘 12-19 16:00:00 EST

18.65

-0.37

-1.95%

盘后18.65

+0.000.00%

19:39 EST

最高19.36	最低18.60	成交量204.12万
今开19.25	昨收19.02	日振幅4.00%
总市值16.81亿	流通市值15.20亿	总股本9,016万
成交额3,844万	换手率2.51%	流通股本8,148万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":18.65,"timestamp":1734642000000,"preClose":19.02,"halted":0,"volume":2041241,"hourTrading":{"tag":"盘后","latestPrice":18.65,"preClose":18.65,"latestTime":"19:39 EST","volume":87959,"amount":1640410.1398,"timestamp":1734655167739},"delay":0,"floatShares":81476510,"shares":90155072,"eps":-0.804877,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.37,"latestTime":"12-19 16:00:00 EST","open":19.25,"high":19.36,"low":18.6,"amount":38444653.385601,"amplitude":0.039958,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.804877,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734685200000},"adr":0,"listingDate":1554955200000,"adjPreClose":19.02,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":19.69,"preClose":19.02,"latestTime":"08:52 EST","volume":64,"amount":1227.160064,"timestamp":1734616324698},"postHourTrading":{"tag":"盘后","latestPrice":18.65,"preClose":18.65,"latestTime":"19:39 EST","volume":87959,"amount":1640410.1398,"timestamp":1734655167739},"volumeRatio":2.092562,"impliedVol":0.5087,"impliedVolPercentile":0.5873},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2492094565","title":"中颖电子12月18日在互动平台上表示，中颖PD协议芯片将在明年启动市场推广。","url":"https://stock-news.laohu8.com/highlight/detail?id=2492094565","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492094565?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:13","pubTimestamp":1734484424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1169589451.USD","159813","BK0125","PD","BK4023","BK0028","300327","BK0214","BK0152","BK0109","LU1169590202.USD"],"gpt_icon":0},{"id":"2492930566","title":"日本国立材料研究所廖梅勇团队实现金刚石DUV探测器低电压高增益新突破！","url":"https://stock-news.laohu8.com/highlight/detail?id=2492930566","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492930566?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:45","pubTimestamp":1734432300,"startTime":"0","endTime":"0","summary":"金刚石作为一种具有超宽带隙、高热导率、化学惰性、高绝缘性和辐射抗性的材料，被认为是制造DUV光电探测器的理想候选材料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-17/doc-inczukxm4793002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169590202.USD","LU1169589451.USD","BK4023","BK4110","PD","SCD","PMT"],"gpt_icon":0},{"id":"2490008702","title":"21健讯Daily｜两部门发文完善医药集中带量采购和执行工作机制；默沙东PD-1抑制剂帕博利珠单抗新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2490008702","media":"21综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490008702?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:50","pubTimestamp":1733881838,"startTime":"0","endTime":"0","summary":"政策动向两部门发文完善医药集中带量采购和执行工作机制12月10日，国家医保局会同国家卫生健康委印发《关于完善医药集中带量采购和执行工作机制的通知》。药械审批默沙东PD-1抑制剂帕博利珠单抗新适应症获批12月10日，默沙东宣布，其PD-1抑制剂帕博利珠单抗新适应症已获NMPA批准，联合放化疗用于国际妇产科联盟2014 III-IVA期宫颈癌患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211102421a1e4ded7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211102421a1e4ded7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU2324357040.USD","LU1917777945.USD","LU0203345920.USD","LU2089984988.USD","PD","BK4023","IE00BBT3K403.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0106261372.USD","MRK","LU1066051225.USD","IE0009355771.USD","LU0238689110.USD","LU0320765489.SGD","LU2468319806.SGD","LU0965509101.SGD","LU1699723380.USD","LU2361044949.HKD","LU1974910355.USD","LU0208291251.USD","LU1066053197.SGD","LU0965509010.AUD","LU0211331839.USD","LU1989772840.SGD","LU1093756168.USD","IE000M9KFDE8.USD","LU1291159041.SGD","BK4550","SG9999001440.SGD","SG9999015358.SGD","SG9999002232.USD","IE00B4R5TH58.HKD","LU0861579265.USD","LU0070302665.USD","LU1057294990.SGD","LU1585245621.USD","BK4534","SG9999014559.SGD","IE00BJT1NW94.SGD","LU1989772923.USD","LU1983299246.USD","LU2112291526.USD","LU1116320901.HKD","LU0985320562.USD","LU1169590202.USD","IE00BLSP4239.USD","SG9999001176.USD","LU0006306889.USD"],"gpt_icon":0},{"id":"2490078184","title":"和誉-B(02256)：口服PD-L1小分子抑制剂ABSK043联合伏美替尼治疗非小细胞肺癌的 II期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2490078184","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490078184?lang=zh_cn&edition=full","pubTime":"2024-12-11 07:04","pubTimestamp":1733871884,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属和誉医药宣布已完成“一项评估ABSK043联合伏美替尼治疗 EGFR突变阳性的局部晚期或转移性非小细胞肺癌患者的有效性和安全性的II期开放性临床研究”的首例患者给药。ABSK043是由和誉医药自主研发的一款口服生物利用度好、高选择性、高活性的小分子PD-L1 抑制剂，目前正在开发用于治疗多种恶性肿瘤。ABSK043和伏美替尼的联合治疗，有望为EGFR突变的晚期肺癌患者带来更好的临床抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","PD","BK1161","BK4023","LU1169589451.USD","LU1169590202.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2490632190","title":"默沙东PD-1抑制剂可瑞达在华获批局部晚期宫颈癌治疗适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2490632190","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490632190?lang=zh_cn&edition=full","pubTime":"2024-12-10 15:20","pubTimestamp":1733815201,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月10日，默沙东宣布，其PD-1抑制剂帕博利珠单抗（商品名：可瑞达?）已获得中国国家药品监督管理局（NMPA）批准，联合放化疗用于国际妇产科联盟（FIGO）2014III-IVA期宫颈癌患者的治疗。此次新适应证获批是基于全球III期临床试验KEYNOTE-A18研究数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412103264168935.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412103264168935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1934455194.USD","LU0965509101.SGD","IE00B1BXHZ80.USD","LU1116320901.HKD","LU1291159041.SGD","LU1061106388.HKD","BK4007","IE0009355771.USD","BK4588","LU1066051225.USD","IE00BJJMRZ35.SGD","LU2023250843.SGD","BK4533","IE00BJT1NW94.SGD","IE00BN8TJ469.HKD","LU2461242641.AUD","LU1169589451.USD","MRK","LU0965508806.USD","SG9999015341.SGD","SG9999015358.SGD","BK4516","LU0861579265.USD","LU2089984988.USD","LU2468319806.SGD","LU0320765489.SGD","LU2106854487.HKD","SG9999014567.USD","LU0208291251.USD","LU1989771016.USD","SG9999001440.SGD","PD","SG9999014559.SGD","LU1974910355.USD","LU1057294990.SGD","LU0070302665.USD","SG9999001176.USD","IE00BLSP4452.SGD","LU1169590202.USD","SG9999014542.SGD","IE0002141913.USD","LU1941712264.USD","LU0203345920.USD","LU1585245621.USD","BK4559","LU1699723380.USD","BK4023","LU1066051498.USD","IE000M9KFDE8.USD","LU0006306889.USD"],"gpt_icon":0},{"id":"2490805084","title":"默沙东PD-1抑制剂可瑞达在华获批局部晚期宫颈癌治疗适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2490805084","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490805084?lang=zh_cn&edition=full","pubTime":"2024-12-10 14:57","pubTimestamp":1733813845,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["PD","03347","IE00B2B36J28.USD","LU1116320901.HKD","LU2468319806.SGD","SG9999001176.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0861579265.USD","LU1941712264.USD","LU1983299246.USD","IVA","LU0070302665.USD","SG9999014559.SGD","BK4139","SG9999014567.USD","LU2106854487.HKD","LU2361044865.SGD","LU1989772840.SGD","LU1989772923.USD","MRK","LU1037948541.HKD","LU1934455277.USD","LU1093756168.USD","IE00B1BXHZ80.USD","LU1066051498.USD","BK4533","LU1989771016.USD","BK1141","BK4134","SG9999001440.SGD","LU0289739699.SGD","LU1430594728.SGD","BK1583","LU1093756325.SGD","SG9999002224.SGD","LU0203345920.USD","LU1057294990.SGD","LU0265550946.USD","LU2361045086.USD","III","LU0265550359.USD","LU2023250843.SGD","LU0122379950.USD","LU0965508806.USD","LU1066051811.HKD","BK4588","LU0234572021.USD","LU2461242641.AUD","SG9999002232.USD"],"gpt_icon":0},{"id":"2489427662","title":"和誉(02256)：已于欧洲肿瘤内科学会亚洲年会展示口服PD-L1抑制剂ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489427662","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489427662?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:26","pubTimestamp":1733459170,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)公告，公司之附属公司上海和誉生物医药科技有限公司（“和誉医药”）宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会（“ESMO Asia 2024”）上以口头报告形式展示其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK1161","LU1169589451.USD","LU1169590202.USD","LU2488822045.USD","BK4023","02256"],"gpt_icon":0},{"id":"2489876422","title":"和誉-B(02256)：和誉医药以口头报告形式展示其口服PD-L1抑制剂 ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489876422","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489876422?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:04","pubTimestamp":1733457895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，该公司的附属公司上海和誉生物医药科技有限公司宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会上以口头报告形式展示其自主研发的口服PD-L1 抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。研究结果表明，在600mg-1000mg BID剂量组，ABSK043单药具有良好的安全性和抗肿瘤活性。这些发现将持续支持ABSK043在EGFR突变肺癌和各种其他实体瘤中的进一步研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1169590202.USD","09939","BK1161","BK4023","LU2488822045.USD","LU1169589451.USD","02256","BK1515","PD","159938"],"gpt_icon":0},{"id":"2489434152","title":"蓝梦 PD快充数据线7.9元秒杀抢购中","url":"https://stock-news.laohu8.com/highlight/detail?id=2489434152","media":"ZOL中关村在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489434152?lang=zh_cn&edition=full","pubTime":"2024-12-05 18:15","pubTimestamp":1733393745,"startTime":"0","endTime":"0","summary":"一款高品质的蓝梦 PD快充数据线正在促销中。这款蓝梦 PD快充数据线采用了5芯TPE材料制作而成，具有出色的耐久性和稳定性。此外，数据线还具备良好的柔软度和弹性，使用起来更加舒适稳定。这款蓝梦 PD快充数据线非常适合苹果、华为和小米等品牌的手机用户使用。这次促销活动是一个绝佳的机会，如果您正在寻找一条高品质、高效率的数据线，那么这款蓝梦 PD快充数据线将是您的不二之选。不要再等待了，快来抢购吧！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_tech","url":"https://tech.sina.cn/mobile/xp/2024-12-05/detail-incymitm2842339.d.html?vt=4","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}.weibo_user{#sourceStyle#; margin-bottom: 0; display: inline-block;}.weibo_time{#sourceStyle#};","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .j_float_wbro, .j_article_wbreco","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://tech.sina.cn/mobile/xp/2024-12-05/detail-incymitm2842339.d.html?vt=4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_tech","symbols":["BK4023","PD","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2489943358","title":"新股前瞻|还在PD-1赛道加塞，翰思艾泰商业化究竟有多落后？","url":"https://stock-news.laohu8.com/highlight/detail?id=2489943358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489943358?lang=zh_cn&edition=full","pubTime":"2024-12-05 17:44","pubTimestamp":1733391880,"startTime":"0","endTime":"0","summary":"又一家押注PD-1热门赛道的创新药企开启赴港上市之路。PD-1赛道内卷严重，研发进展不确定性仍存作为翰思艾泰的核心产品，HX009的研发进度无疑备受关注。今年的医保谈判中，四款国产PD-1抑制剂纳入医保，最高降价幅度达85%。创新药企的市场估值离不开其在研管线的潜在市场前景，在PD-1赛道众多竞争者环伺的当下，主要产品的临床试验均处于早期的翰思艾泰或难获得太多估值溢价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK4023","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2488890428","title":"健讯Daily｜默沙东抗PD-1单抗在华获批第四项肺癌适应证；舒泰神第二大股东减持股份达到 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488890428","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488890428?lang=zh_cn&edition=full","pubTime":"2024-12-04 08:37","pubTimestamp":1733272623,"startTime":"0","endTime":"0","summary":"通知公布的基本医疗服务项目价格为广东省最高限价，各地市于2024年12月30日前公布具体价格并执行。默沙东抗PD-1单抗在华获批第四项肺癌适应证12月3日，默沙东宣布，其PD-1抑制剂帕博利珠单抗已获得中国国家药品监督管理局批准，联合含铂化疗新辅助治疗并在手术后继续帕博利珠单抗单药辅助治疗，用于可手术切除的II、IIIA和IIIB期非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204084907a26aa7fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204084907a26aa7fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1934455194.USD","LU1037948897.HKD","IE00BBT3K403.USD","LU1169590202.USD","LU1057294990.SGD","LU2324357040.USD","IE00BJT1NW94.SGD","LU0861579265.USD","LU2112291526.USD","LU1116320901.HKD","LU1989772840.SGD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0122379950.USD","BK4516","LU1430594728.SGD","LU0266013472.USD","LU1571399168.USD","LU1934455863.HKD","MRK","PD","SGXZ57979304.SGD","LU1116320737.USD","SG9999015341.SGD","LU1066051498.USD","LU1066051225.USD","LU1974910355.USD","IE00B2B36J28.USD","LU1917777945.USD","LU1941712264.USD","SG9999002224.SGD","LU2106854487.HKD","LU1934455277.USD","LU0965509101.SGD","SG9999001176.USD","LU2361045086.USD","IE00B1BXHZ80.USD","LU0265550946.USD","SG9999013999.USD","LU1169589451.USD","SG9999001440.SGD","IE00BN8TJ469.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0965509283.SGD","IE00BFTCPJ56.SGD","LU2461242641.AUD","IE00B4R5TH58.HKD","LU0203347892.USD","BK4007"],"gpt_icon":0},{"id":"2488242915","title":"复宏汉霖PD-1汉斯状获批非鳞状非小细胞肺癌新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2488242915","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488242915?lang=zh_cn&edition=full","pubTime":"2024-12-03 19:47","pubTimestamp":1733226459,"startTime":"0","endTime":"0","summary":"2024年12月3日，复宏汉霖宣布，公司自主研发的创新型抗PD-1单抗H药汉斯状（通用名：斯鲁利单抗注射液）正式获得国家药品监督管理局（NMPA）批准，联合培美曲塞和卡铂适用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌（nsNSCLC）的一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412033257949911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412033257949911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169590202.USD","LU1169589451.USD","02696","PD","BK1161","BK4023"],"gpt_icon":0},{"id":"2488994602","title":"复宏汉霖获批PD-1单抗新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2488994602","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488994602?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:59","pubTimestamp":1733219954,"startTime":"0","endTime":"0","summary":"财中社12月3日电复宏汉霖（02696）发布公告，国家药品监督管理局已批准公司自主研发的创新抗PD-1单抗汉斯状?（斯鲁利单抗注射液）联合化疗用于局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）的一线治疗新适应症的上市注册申请（NDA）。此次获批基于一项随机、双盲、多中心的3期临床研究，结果显示汉斯状?联合化疗的无进展生存期（PFS）显著延长，达到预设的优效标准，且安全性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412033257885277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","PD","LU1169590202.USD","LU1169589451.USD","BK1161","BK4023"],"gpt_icon":0},{"id":"2486736461","title":"君实生物：拓益新增适应症纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486736461","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486736461?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:22","pubTimestamp":1732782121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["PD","01877","LU1169589451.USD","688180","BK4023","BK0239","BK1515","BK1583","LU1169590202.USD","BK1161"],"gpt_icon":0},{"id":"2486350237","title":"百济神州：商业化产品多项新增适应症被纳入2024国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486350237","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486350237?lang=zh_cn&edition=full","pubTime":"2024-11-28 14:52","pubTimestamp":1732776752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1500","BK1161","BK4139","LU2328871848.SGD","LU1169590202.USD","BK4505","LU1969619763.USD","BK4023","BK1588","PD","06160","LU0307460666.USD","BK4588","LU0588546209.SGD","BK4504","BK4535","BK4526","BK0239","BK4548","BK1583","LU1169589451.USD","BK4585","688235","BGNE"],"gpt_icon":0},{"id":"2486820656","title":"Pagerduty, Inc.盘中异动 早盘急速拉升5.13%报21.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486820656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486820656?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:30","pubTimestamp":1732717832,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时30分，Pagerduty, Inc.股票出现异动，股价急速拉升5.13%。截至发稿，该股报21.98美元/股，成交量4.5546万股，换手率0.05%，振幅0.62%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.00%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223032971a8d9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223032971a8d9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2486891187","title":"刚刚！正大天晴 PD-L1 “贝莫苏拜单抗”获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2486891187","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486891187?lang=zh_cn&edition=full","pubTime":"2024-11-27 12:14","pubTimestamp":1732680840,"startTime":"0","endTime":"0","summary":"截图来源：企业官微贝莫苏拜单抗 是正大天晴自主研发的一款全新序列的创新人源化 PD-L1 单克隆抗体。2022 年 4 月，贝莫苏拜单抗子宫内膜癌适应症曾被 CDE 纳入突破性治疗。此次贝莫苏拜单抗新适应症的获批，将为复发性或转移性子宫内膜癌后线治疗提供新选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-27/doc-incxnmtq6892463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2486783054","title":"PagerDuty Inc 报告截至 10 月 31 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2486783054","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486783054?lang=zh_cn&edition=full","pubTime":"2024-11-27 06:02","pubTimestamp":1732658565,"startTime":"0","endTime":"0","summary":"PagerDuty Inc 报告截至 10 月 31 日的季度业绩 - 收益摘要PagerDuty Inc PD.N 公布的截至 10 月 31 日的季度调整后每股收益为 25 美分，高于去年同期的每股收益 21 美分。13位分析师对该季度的平均预期为每股收益17美分。华尔街预期为每股收益 16 美分至 19 美分。PagerDuty Inc公布的本季度每股收益为亏损7美分。该公司当季亏损 656 万美元。PagerDuty Inc 本季度股价上涨了 11.3%，今年迄今为止亏损了 10.8%。华尔街对 PagerDuty 公司 12 个月目标价的中位数为 21.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3S3MX1SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169589451.USD","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"2486708965","title":"先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708965","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708965?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:59","pubTimestamp":1732539575,"startTime":"0","endTime":"0","summary":"先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局受理，用于成人2型糖尿病患者血糖控制适应症。正大天晴彼时新闻稿表示，将就该联合疗法的新适应症向CDE递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B2B36J28.USD","IE0002141913.USD","LU1929549753.HKD","LU2602419157.SGD","IE00B3PB1722.GBP","PD","IE00B4R5TH58.HKD","IE0002270589.USD","LU2089984988.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU2347655156.SGD","LU0203345920.USD","LU0234572021.USD","BK4023","LU0795875086.SGD","BK4585","LU0320765646.SGD","LU1732800096.USD","IE0009355771.USD","GLP","LU0795875169.SGD","LU1162221912.USD","LU1430594728.SGD","LU0098860793.USD","LU0345770308.USD","LU1732799900.SGD","LU0912757837.SGD","BK4144","LU1032955483.USD","LU1074936037.SGD","LU0640476718.USD","LU2468319806.SGD","LU0122379950.USD","LU1267930813.SGD","BK4581","LU1244550494.USD","IE00BVYPNV92.GBP","BK4590","IE00BFTCPJ56.SGD","LU0203347892.USD","LU0234570918.USD","LU1221951046.USD","IE00B1BXHZ80.USD","IE000M9KFDE8.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","IE00BVYPNW00.USD","JNJ","LU1169589451.USD"],"gpt_icon":0},{"id":"2486089135","title":"PD-1王炸搭档迎来重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2486089135","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486089135?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:04","pubTimestamp":1732536240,"startTime":"0","endTime":"0","summary":"近日，Replimune Group宣布向FDA提交溶瘤病毒疗法RP1治疗晚期黑色素瘤的生物制品许可申请，本次BLA申请通过加速批准通道提交，同时公司宣布了FDA授予RP1联用O药在同适应症中的突破性疗法认定。另外，RP1可以选择性感染并杀死肿瘤细胞，不会对正常细胞造成严重损害，这也保证了其治疗的安全性。即便是PD-1单药，二线治疗肢端和黏膜黑色素瘤的ORR分别为14-15.8%和0-13.3%。过往已有临床数据初步验证了“溶瘤病毒+PD-1或其他免疫检查点”能够增强对于不同肿瘤的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/25200445661532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["PD","BK4023","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":-0.0795},{"period":"1month","weight":-0.0021},{"period":"3month","weight":0.0327},{"period":"6month","weight":-0.1285},{"period":"1year","weight":-0.2071},{"period":"ytd","weight":-0.1944}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":-0.0071},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.0764},{"period":"1year","weight":0.2517},{"period":"ytd","weight":0.2331}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.052063},{"month":2,"riseRate":0.6,"avgChangeRate":-0.030334},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028164},{"month":4,"riseRate":0.4,"avgChangeRate":-0.029577},{"month":5,"riseRate":0.333333,"avgChangeRate":0.0049},{"month":6,"riseRate":0.666667,"avgChangeRate":0.013501},{"month":7,"riseRate":0.5,"avgChangeRate":0.011648},{"month":8,"riseRate":0.5,"avgChangeRate":-0.00702},{"month":9,"riseRate":0,"avgChangeRate":-0.131039},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037852},{"month":11,"riseRate":0.666667,"avgChangeRate":0.066825},{"month":12,"riseRate":0.5,"avgChangeRate":0.037313}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}